Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation

James L. Velianou, Verghese Mathew, Stephanie H. Wilson, Gregory W. Barsness, Diane E. Grill, David Holmes

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM) is associated with higher rates of adverse cardiac events. Recent data suggest that adverse events are reduced in DM after PCI using stents with abciximab. We performed a retrospective analysis of a prospective PCI registry for all patients with DM who underwent stent placement at the Mayo Clinic from 1995 to 1997 (n = 570), and divided them into 2 groups based on whether abciximab was administered. Characterization and comparison of the clinical and angiographic variables, procedural outcomes, and short- and long-term event rates between groups was performed. The baseline clinical characteristics of the groups were similar, but patients treated with abciximab were more likely to be men with a lower left ventricular ejection fraction. Patients treated with abciximab had more multivessel intervention, saphenous vein graft intervention, and thrombus before intervention. The 30-day mortality rate (0.6% vs 3.0%, p = 0.03) and repeat PCI (0% vs 1.1%, p = 0.03) was lower in patients treated with abciximab. The 30-day rates of bypass surgery, myocardial infarction (MI), and a composite of death, MI, and revascularization were similar. The 1-year event rates did not differ significantly between patients taking and not taking abciximab for the end points of death (8.9% vs 8.8%, p = 0.97), MI (13.3% vs 11.4%, p = 0.57), bypass surgery (10.3% vs 6.2%, p = 0.20), repeat PCI (14.7% vs 15.9%, p = 0.76), and a composite of death, MI, and revascularization (30.4% vs 26.7%, p = 0.43). After adjusting for baseline variables, abciximab did not influence the occurrence of late adverse events. Copyright (C) 2000 Excerpta Medica Inc.

Original languageEnglish (US)
Pages (from-to)1063-1068
Number of pages6
JournalAmerican Journal of Cardiology
Volume86
Issue number10
DOIs
StatePublished - Nov 15 2000

Fingerprint

Stents
Diabetes Mellitus
Percutaneous Coronary Intervention
Myocardial Infarction
Myocardial Revascularization
Saphenous Vein
abciximab
Stroke Volume
Registries
Thrombosis
Transplants
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation. / Velianou, James L.; Mathew, Verghese; Wilson, Stephanie H.; Barsness, Gregory W.; Grill, Diane E.; Holmes, David.

In: American Journal of Cardiology, Vol. 86, No. 10, 15.11.2000, p. 1063-1068.

Research output: Contribution to journalArticle

Velianou, James L. ; Mathew, Verghese ; Wilson, Stephanie H. ; Barsness, Gregory W. ; Grill, Diane E. ; Holmes, David. / Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation. In: American Journal of Cardiology. 2000 ; Vol. 86, No. 10. pp. 1063-1068.
@article{3c24af0c44c84f168516461853c070a5,
title = "Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation",
abstract = "Percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM) is associated with higher rates of adverse cardiac events. Recent data suggest that adverse events are reduced in DM after PCI using stents with abciximab. We performed a retrospective analysis of a prospective PCI registry for all patients with DM who underwent stent placement at the Mayo Clinic from 1995 to 1997 (n = 570), and divided them into 2 groups based on whether abciximab was administered. Characterization and comparison of the clinical and angiographic variables, procedural outcomes, and short- and long-term event rates between groups was performed. The baseline clinical characteristics of the groups were similar, but patients treated with abciximab were more likely to be men with a lower left ventricular ejection fraction. Patients treated with abciximab had more multivessel intervention, saphenous vein graft intervention, and thrombus before intervention. The 30-day mortality rate (0.6{\%} vs 3.0{\%}, p = 0.03) and repeat PCI (0{\%} vs 1.1{\%}, p = 0.03) was lower in patients treated with abciximab. The 30-day rates of bypass surgery, myocardial infarction (MI), and a composite of death, MI, and revascularization were similar. The 1-year event rates did not differ significantly between patients taking and not taking abciximab for the end points of death (8.9{\%} vs 8.8{\%}, p = 0.97), MI (13.3{\%} vs 11.4{\%}, p = 0.57), bypass surgery (10.3{\%} vs 6.2{\%}, p = 0.20), repeat PCI (14.7{\%} vs 15.9{\%}, p = 0.76), and a composite of death, MI, and revascularization (30.4{\%} vs 26.7{\%}, p = 0.43). After adjusting for baseline variables, abciximab did not influence the occurrence of late adverse events. Copyright (C) 2000 Excerpta Medica Inc.",
author = "Velianou, {James L.} and Verghese Mathew and Wilson, {Stephanie H.} and Barsness, {Gregory W.} and Grill, {Diane E.} and David Holmes",
year = "2000",
month = "11",
day = "15",
doi = "10.1016/S0002-9149(00)01160-7",
language = "English (US)",
volume = "86",
pages = "1063--1068",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation

AU - Velianou, James L.

AU - Mathew, Verghese

AU - Wilson, Stephanie H.

AU - Barsness, Gregory W.

AU - Grill, Diane E.

AU - Holmes, David

PY - 2000/11/15

Y1 - 2000/11/15

N2 - Percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM) is associated with higher rates of adverse cardiac events. Recent data suggest that adverse events are reduced in DM after PCI using stents with abciximab. We performed a retrospective analysis of a prospective PCI registry for all patients with DM who underwent stent placement at the Mayo Clinic from 1995 to 1997 (n = 570), and divided them into 2 groups based on whether abciximab was administered. Characterization and comparison of the clinical and angiographic variables, procedural outcomes, and short- and long-term event rates between groups was performed. The baseline clinical characteristics of the groups were similar, but patients treated with abciximab were more likely to be men with a lower left ventricular ejection fraction. Patients treated with abciximab had more multivessel intervention, saphenous vein graft intervention, and thrombus before intervention. The 30-day mortality rate (0.6% vs 3.0%, p = 0.03) and repeat PCI (0% vs 1.1%, p = 0.03) was lower in patients treated with abciximab. The 30-day rates of bypass surgery, myocardial infarction (MI), and a composite of death, MI, and revascularization were similar. The 1-year event rates did not differ significantly between patients taking and not taking abciximab for the end points of death (8.9% vs 8.8%, p = 0.97), MI (13.3% vs 11.4%, p = 0.57), bypass surgery (10.3% vs 6.2%, p = 0.20), repeat PCI (14.7% vs 15.9%, p = 0.76), and a composite of death, MI, and revascularization (30.4% vs 26.7%, p = 0.43). After adjusting for baseline variables, abciximab did not influence the occurrence of late adverse events. Copyright (C) 2000 Excerpta Medica Inc.

AB - Percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM) is associated with higher rates of adverse cardiac events. Recent data suggest that adverse events are reduced in DM after PCI using stents with abciximab. We performed a retrospective analysis of a prospective PCI registry for all patients with DM who underwent stent placement at the Mayo Clinic from 1995 to 1997 (n = 570), and divided them into 2 groups based on whether abciximab was administered. Characterization and comparison of the clinical and angiographic variables, procedural outcomes, and short- and long-term event rates between groups was performed. The baseline clinical characteristics of the groups were similar, but patients treated with abciximab were more likely to be men with a lower left ventricular ejection fraction. Patients treated with abciximab had more multivessel intervention, saphenous vein graft intervention, and thrombus before intervention. The 30-day mortality rate (0.6% vs 3.0%, p = 0.03) and repeat PCI (0% vs 1.1%, p = 0.03) was lower in patients treated with abciximab. The 30-day rates of bypass surgery, myocardial infarction (MI), and a composite of death, MI, and revascularization were similar. The 1-year event rates did not differ significantly between patients taking and not taking abciximab for the end points of death (8.9% vs 8.8%, p = 0.97), MI (13.3% vs 11.4%, p = 0.57), bypass surgery (10.3% vs 6.2%, p = 0.20), repeat PCI (14.7% vs 15.9%, p = 0.76), and a composite of death, MI, and revascularization (30.4% vs 26.7%, p = 0.43). After adjusting for baseline variables, abciximab did not influence the occurrence of late adverse events. Copyright (C) 2000 Excerpta Medica Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034670115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034670115&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(00)01160-7

DO - 10.1016/S0002-9149(00)01160-7

M3 - Article

C2 - 11074200

AN - SCOPUS:0034670115

VL - 86

SP - 1063

EP - 1068

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 10

ER -